Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lord O’Neill Blames Governments And Pharma For Faltering AMR Progress

O'Neill assessed the antibiotic 'State Of Play' in a Chatham House AMR progress report

Executive Summary

Three years after completion of his high-profile AMR Review, Jim O’Neill warns that global progress on antimicrobial resistance has slowed dangerously.

You may also be interested in...



UK’s O’Neill ‘Frustrated’ By G20’s ‘Paltry’ AMR Message

Jim O’Neill, the British economist who helped put the dangers of antimicrobial resistance firmly on the world stage, says he’s “frustrated” by the G20’s lack of focus on AMR during its Japan summit.

Iovance TIL Appeal Seen Luring Potential Buyers

Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.

Novartis’s Beovu Launch Clouded By Safety Worries

New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.

Topics

UsernamePublicRestriction

Register

SC125994

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel